This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Treatment of minimal change disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The management of minimal change nephropathy involves:

  • diuretics should be used with care, avoiding hyponatraemia and a further drop in intravascular volume
  • salt-poor albumin is used in a few patients
  • restrict fluid intake while the patient is oedematous
  • prophylactic penicillin if oedematous
  • 90% of children respond to steroids within 8 weeks

Immunosuppression (cyclophosphomide, ciclosporin, ritixumab) may be indicated if there are early/frequent relapses or steroid side-effects/dependence.

A remission that lasts three years is usually permanent.

With respect to interventions for minimal change disease in adults a systematic review concluded (1):

  • concludes calcineurin inhibitors and mycophenolate probably make little or no difference to rate of remission, partial remission or relapse vs prednisolone, but calcineurin inhibitors may reduce adverse effects

Reference:

  • Azukaitis K, Palmer SC, Strippoli GFM, Hodson EM. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD001537. DOI: 10.1002/14651858.CD001537.pub5

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.